The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
New aims and next steps for adult ALL induction therapy
The importance of pharmacists in clinical trials and therapy delivery
Why do charities need to keep funding research into leukemia and blood cancer in general?
The future of cancer therapy innovation